Diabetes, Vol 48, Issue 5 1026-1034, Copyright © 1999 by American Diabetes Association

ARTICLES

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)

AA Young, BR Gedulin, S Bhavsar, N Bodkin, C Jodka, B Hansen and M Denaro
Amylin Pharmaceuticals, San Diego, California 92121, USA. ayoung@amylin.com

Exendin-4 is a 39 amino acid peptide isolated from the salivary secretions of the Gila monster (Heloderma suspectum). It shows 53% sequence similarity to glucagon-like peptide (GLP)-1. Unlike GLP-1, exendin-4 has a prolonged glucose-lowering action in vivo. We compared the potency and duration of glucose-lowering effects of exendin-4 and GLP-1 in hyperglycemic db/db and ob/ob mice. Whereas reductions in plasma glucose of up to 35% vanished within 1 h with most doses of GLP-1, the same doses of exendin-4 resulted in a similar glucose-lowering effect that persisted for >4 h. Exendin-4 was 5,530-fold more potent than GLP-1 in db/db mice (effective doses, 50% [ED50s] of 0.059 microg/kg +/-0.15 log and 329 microg/kg+/-0.22 log, respectively) and was 5,480-fold more potent in ob/ob mice (ED50s of 0.136 microg/kg+/-0.10 log and 744 microg/kg+/-0.21 log, respectively) when the percentage fall in plasma glucose at 1 h was used as the indicator response. Exendin-4 dose-dependently accelerated glucose lowering in diabetic rhesus monkeys by up to 37% with an ED50 of 0.25 microg/kg +/-0.09 log. In two experiments in which diabetic fatty Zucker rats were injected subcutaneously twice daily for 5-6 weeks with doses of exendin-4 up to 100 microg x rat(-1) x day(-1) (approximately 250 microg/kg), HbA1c was reduced relative to saline-injected control rats. Exendin-4 treatment was also associated in each of these experiments with weight loss and improved insulin sensitivity, as demonstrated by increases of up to 32 and 49%, respectively, in the glucose infusion rate (GIR) in the hyperinsulinemic euglycemic clamp. ED50s for weight loss and the increase in clamp GIR were 1.0 microg/kg+/-0.15 log and 2.4 microg/kg+/-0.41 log, respectively. In conclusion, acute and chronic administration of exendin-4 has demonstrated an antidiabetic effect in several animal models of type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. J. Lamont and D. J. Drucker Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat Fed Mice Diabetes, January 1, 2008; 57(1): 190 - 198. [Abstract] [Full Text] [PDF]

				N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells Endocrinology, November 1, 2007; 148(11): 5136 - 5144. [Abstract] [Full Text] [PDF]

				C. M. Christel, D. F. DeNardo, and S. M. Secor Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum) J. Exp. Biol., October 1, 2007; 210(19): 3430 - 3439. [Abstract] [Full Text] [PDF]

				K. A. Scott and T. H. Moran The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R983 - R987. [Abstract] [Full Text] [PDF]

				D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1487 - 1493. [Abstract] [Full Text] [PDF]

				N. M. Thompson, A. M. Norman, S. S. Donkin, R. R. Shankar, M. H. Vickers, J. L. Miles, and B. H. Breier Prenatal and Postnatal Pathways to Obesity: Different Underlying Mechanisms, Different Metabolic Outcomes Endocrinology, May 1, 2007; 148(5): 2345 - 2354. [Abstract] [Full Text] [PDF]

				C. N. Andrews, A. E. Bharucha, M. Camilleri, P. A. Low, B. Seide, D. Burton, K. Baxter, and A. R. Zinsmeister Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1359 - G1365. [Abstract] [Full Text] [PDF]

				D. Chen, J. Liao, N. Li, C. Zhou, Q. Liu, G. Wang, R. Zhang, S. Zhang, L. Lin, K. Chen, et al. From the Cover: A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice PNAS, January 16, 2007; 104(3): 943 - 948. [Abstract] [Full Text] [PDF]

				R K. Campbell Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60. [Abstract] [Full Text] [PDF]

				J.-H. Kang, M.-J. Kim, H.-I. Jang, K.-H. Koh, K.-S. Yum, D.-J. Rhie, S. H. Yoon, S. J. Hahn, M.-S. Kim, and Y.-H. Jo Proximal cyclic AMP response element is essential for exendin-4 induction of rat EGR-1 gene Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E215 - E222. [Abstract] [Full Text] [PDF]

				D. L. Williams, D. G. Baskin, and M. W. Schwartz Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation Diabetes, December 1, 2006; 55(12): 3387 - 3393. [Abstract] [Full Text] [PDF]

				B. D. Green, K. S. Lavery, N. Irwin, F. P. M. O'Harte, P. Harriott, B. Greer, C. J. Bailey, and P. R. Flatt Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic beta-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 914 - 921. [Abstract] [Full Text] [PDF]

				G. M. Bray Exenatide Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 411 - 418. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				A. Aziz, G. H. Anderson, A. Giacca, and F. Cho Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R688 - R694. [Abstract] [Full Text] [PDF]

				B D Green, N Irwin, V A Gault, C J Bailey, F P M O'Harte, and P R Flatt Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice J. Endocrinol., May 1, 2005; 185(2): 307 - 317. [Abstract] [Full Text] [PDF]

				D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Diabetes Care, May 1, 2005; 28(5): 1083 - 1091. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1092 - 1100. [Abstract] [Full Text] [PDF]

				E. Blase, K. Taylor, H.-y. Gao, M. Wintle, and M. Fineman Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin-4) in Healthy Subjects J. Clin. Pharmacol., May 1, 2005; 45(5): 570 - 577. [Abstract] [Full Text] [PDF]

				K. Dungan and J. B. Buse Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide Clin. Diabetes, April 1, 2005; 23(2): 56 - 62. [Abstract] [Full Text] [PDF]

				B. R. Gedulin, S. E. Nikoulina, P. A. Smith, G. Gedulin, L. L. Nielsen, A. D. Baron, D. G. Parkes, and A. A. Young Exenatide (Exendin-4) Improves Insulin Sensitivity and {beta}-Cell Mass in Insulin-Resistant Obese fa/fa Zucker Rats Independent of Glycemia and Body Weight Endocrinology, April 1, 2005; 146(4): 2069 - 2076. [Abstract] [Full Text] [PDF]

				O. G. Kolterman, D. D. Kim, L. Shen, J. A. Ruggles, L. L. Nielsen, M. S. Fineman, and A. D. Baron Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm., January 15, 2005; 62(2): 173 - 181. [Abstract] [Full Text] [PDF]

				S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]

				L. L. Baggio, J.-G. Kim, and D. J. Drucker Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R-Dependent Glucose Homeostasis In Vivo Diabetes, December 1, 2004; 53(suppl_3): S205 - S214. [Abstract] [Full Text] [PDF]

				J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Diabetes Care, November 1, 2004; 27(11): 2628 - 2635. [Abstract] [Full Text] [PDF]

				J. Dupre, M. T. Behme, and T. J. McDonald Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3469 - 3473. [Abstract] [Full Text] [PDF]

				C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF]

				D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]

				C. Thorkildsen, S. Neve, B. D. Larsen, E. Meier, and J. S. Petersen Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 490 - 496. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				M. S. Fineman, T. A. Bicsak, L. Z. Shen, K. Taylor, E. Gaines, A. Varns, D. Kim, and A. D. Baron Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes Diabetes Care, August 1, 2003; 26(8): 2370 - 2377. [Abstract] [Full Text] [PDF]

				O. G. Kolterman, J. B. Buse, M. S. Fineman, E. Gaines, S. Heintz, T. A. Bicsak, K. Taylor, D. Kim, M. Aisporna, Y. Wang, et al. Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3082 - 3089. [Abstract] [Full Text] [PDF]

				A. Aziz and G. H. Anderson Exendin-4, a GLP-1 Receptor Agonist, Interacts with Proteins and Their Products of Digestion to Suppress Food Intake in Rats J. Nutr., July 1, 2003; 133(7): 2326 - 2330. [Abstract] [Full Text] [PDF]

				J. M. Egan, G. S. Meneilly, and D. Elahi Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1072 - E1079. [Abstract] [Full Text] [PDF]

				H. Yamamoto, T. Kishi, C. E. Lee, B. J. Choi, H. Fang, A. N. Hollenberg, D. J. Drucker, and J. K. Elmquist Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites J. Neurosci., April 1, 2003; 23(7): 2939 - 2946. [Abstract] [Full Text] [PDF]

				J.-G. Kim, L. L. Baggio, D. P. Bridon, J.-P. Castaigne, M. F. Robitaille, L. Jette, C. Benquet, and D. J. Drucker Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate: The Ability to Activate the Glucagon-Like Peptide 1 Receptor In Vivo Diabetes, March 1, 2003; 52(3): 751 - 759. [Abstract] [Full Text] [PDF]

				B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E745 - E752. [Abstract] [Full Text] [PDF]

				F. A. Adatia, L. L. Baggio, Q. Xiao, D. J. Drucker, and P. L. Brubaker Cellular Specificity of Proexendin-4 Processing in Mammalian Cells in Vitro and in Vivo Endocrinology, September 1, 2002; 143(9): 3464 - 3471. [Abstract] [Full Text] [PDF]

				J. A. Pospisilik, S. G. Stafford, H.-U. Demuth, C. H.S. McIntosh, and R. A. Pederson Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat: A Euglycemic-Hyperinsulinemic Clamp Study Diabetes, September 1, 2002; 51(9): 2677 - 2683. [Abstract] [Full Text] [PDF]

				B. Sudre, P. Broqua, R. B. White, D. Ashworth, D. M. Evans, R. Haigh, J.-L. Junien, and M. L. Aubert Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats Diabetes, May 1, 2002; 51(5): 1461 - 1469. [Abstract] [Full Text] [PDF]

				A. Aziz and G. H. Anderson Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats J. Nutr., May 1, 2002; 132(5): 990 - 995. [Abstract] [Full Text] [PDF]

				J.A. Pospisilik, S.G. Stafford, H-U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H.S. McIntosh, and R.A. Pederson Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and {beta}-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats Diabetes, April 1, 2002; 51(4): 943 - 950. [Abstract] [Full Text] [PDF]

				J. M. Egan, A. R. Clocquet, and D. Elahi The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1282 - 1290. [Abstract] [Full Text] [PDF]

				P. J. Larsen, C. Fledelius, L. B. Knudsen, and M. Tang-Christensen Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats Diabetes, November 1, 2001; 50(11): 2530 - 2539. [Abstract] [Full Text] [PDF]

				C. L. Dakin, I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, M. A. Ghatei, and S. R. Bloom Oxyntomodulin Inhibits Food Intake in the Rat Endocrinology, October 1, 2001; 142(10): 4244 - 4250. [Abstract] [Full Text] [PDF]

				C. T. Peters, Y.-H. Choi, P. L. Brubaker, and G. H. Anderson A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats J. Nutr., August 1, 2001; 131(8): 2164 - 2170. [Abstract] [Full Text] [PDF]

				C. M. B. Edwards, S. A. Stanley, R. Davis, A. E. Brynes, G. S. Frost, L. J. Seal, M. A. Ghatei, and S. R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E155 - E161. [Abstract] [Full Text] [PDF]

				M. Szayna, M. E. Doyle, J. A. Betkey, H. W. Holloway, R. G. S. Spencer, N. H. Greig, and J. M. Egan Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats Endocrinology, June 1, 2000; 141(6): 1936 - 1941. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				L. Baggio, F. Adatia, T. Bock, P. L. Brubaker, and D. J. Drucker Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, beta -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice J. Biol. Chem., October 27, 2000; 275(44): 34471 - 34477. [Abstract] [Full Text] [PDF]